IDiyas

For the Inventor, By the Inventor

Shanghai, China

Daxin Gao

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Thousand Oaks, CA (US) (2015)
  • Shanghai, CN (2015 - 2022)

Company Filing History:

goldMedal7 out of 7 
 
Shanghai De Novo Pharmatech Co., Ltd.
 patents

Years Active: 2015-2024

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):
1. 12152051 - Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application (2024-11-26),
2. 11248006 - Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof (2022-02-15),
3. 10669252 - Benzazepine derivative, preparation method, pharmaceutical composition and use thereof (2020-06-02),
4. 10202388 - Fused-ring compounds, pharmaceutical composition and uses thereof (2019-02-12),
5. 9914724 - C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof (2018-03-13),
6. 9216997 - Tri-heterocyclic derivatives, preparation process and uses thereof (2015-12-22),
7. 8999985 - Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof (2015-04-07),

Title: Daxin Gao: Pioneering Patents in Pharmaceutical Innovation

Introduction

Daxin Gao is a notable inventor based in Shanghai, China, recognized for his significant contributions to pharmaceutical innovations. With a total of seven patents to his name, he is at the forefront of developing novel compounds aimed at addressing various medical challenges.

Latest Patents

Among Daxin Gao's latest patents is a groundbreaking cyclic dinucleotide analogue, accompanied by its pharmaceutical composition and applications. This analogue is designed to act as a regulator of the stimulator of interferon genes (STING). It shows promise in treating a diverse range of conditions, including malignant tumors, autoimmune diseases, infectious diseases, and inflammations. Additionally, this compound serves as a potential vaccine adjuvant, enhancing the efficacy of vaccines.

Another noteworthy patent from Gao is the macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one. This invention presents both a pharmaceutical composition and its applications. The compound functions as a Wee1 inhibitor, providing therapeutic effects in chemotherapy and radiotherapy for cancer treatment, demonstrating its effectiveness in inhibiting related signaling pathways.

Career Highlights

Daxin Gao is currently employed at Shanghai De Novo Pharmatech Co., Ltd., where he has made significant strides in pharmaceutical development. His expertise and innovative spirit contribute to the company's mission of advancing healthcare solutions through cutting-edge research.

Collaborations

In his journey as an inventor, Daxin Gao collaborates with esteemed colleagues, including Heping Yang and Shoujun Chen. Together, they combine their expertise to push the boundaries of pharmaceutical research and create impactful solutions in the medical field.

Conclusion

Daxin Gao's inventions exemplify the spirit of innovation in pharmaceuticals. His contributions through patents not only emphasize the importance of research and development but also reflect a commitment to improving health outcomes globally. As he continues his work at Shanghai De Novo Pharmatech Co., Ltd., the medical community eagerly anticipates the advancements that may arise from his ongoing research efforts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…